China biotech startup InventisBio bags a $19M round for early-stage R&D
The flow of venture cash in and out of China’s biotech scene includes a new $19 million round today for Shanghai-based InventisBio, which has been lining up a slate of cancer therapies for Phase I development.
Merck vet and company founder Yaolin Wang tells me that he left the global pharma giant in 2015 to start the company, which has been operating as a virtual outfit with 7 staffers and a crew of support staff at WuXi and other CROs in the country.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.